Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Renal Failure

Association between triglyceride-glucose index and treatment response in primary membranous nephropathy: a retrospective cohort study

  1. 1Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi, China

Abstract

Background/Objectives: The triglyceride-glucose (TyG) index, a marker of insulin resistance, has been linked to chronic kidney disease and proteinuria severity, but its prognostic value for treatment response in primary membranous nephropathy (PMN) is unclear. We evaluated whether baseline TyG predicts 12-month proteinuria remission in PMN.

Methods: We included 363 patients with PMN. The primary outcome was 12-month remission per 2021 KDIGO criteria. Missing covariates were handled by multiple imputation (20 datasets). Multivariable logistic regression adjusted for anti-PLA2R antibody (continuous, per 100 RU/mL), albumin, 24-hour urine protein, age, sex, comorbidities, and treatment group. Sensitivity analyses included TyG tertiles, restriction to standard immunotherapy, complete remission, binary anti-PLA2R status, eGFR adjustment, log-transformed and restricted cubic spline modeling of anti-PLA2R antibody, complete-case analysis, inverse probability of treatment weighting, post-hoc power analysis, and adjustment for treatment switching.

Results: Among 363 patients, 267 (73.6%) achieved remission. Baseline TyG was not independently associated with remission (OR = 0.839, 95% CI: 0.544–1.293, p = 0.425). Higher anti-PLA2R antibody levels were associated with lower odds of remission when modeled continuously (OR per 100 RU/mL = 0.836, 95% CI: 0.704–0.992, p = 0.041), but not when dichotomized (OR = 0.666, 95% CI: 0.213–2.089, p = 0.484). Addition of TyG minimally improved model discrimination (AUC 0.714 to 0.716). Results were consistent across sensitivity analyses.

Conclusions: Baseline TyG was not independently associated with 12-month remission in PMN and provided minimal incremental predictive value. However, a moderate association cannot be excluded given the confidence interval. Anti-PLA2R antibody level showed an inverse association when modeled continuously.

Related

  1. Belimumab with rituximab for the treatment of primary membranous nephropathy
    S. A. Chung, L. Stelzig, M. A. Sherman +15
    medRxivPreprintCC BY-NC-NDFull textGeneral medicinemedRxiv
  2. Treatment‐Line‐Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta‐Analysis
    Abdelrahman M. Elettreby, Ahmed A. Abo Elnaga, Faisal A. Al-Harbi +6
    International Journal of NephrologyPeer-reviewedCC BY 4.0Full textGeneral medicinePMCEurope PMC
  3. Belimumab With Rituximab for the Treatment of Primary Membranous Nephropathy.
    Sharon A Chung, Lia Stelzig, Matthew A Sherman +15
    Kidney international reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Efficacy and influencing factors of rituximab in idiopathic membranous nephropathy : A real-world retrospective study
    Xiaofei Xu, Qiwei Zhou, Subo Li +2
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMCEurope PMC
  5. Infection as a predictor and potential mediator of poor renal outcomes in rituximab-treated primary membranous nephropathy: a retrospective cohort analysis
    Shasha Chen, Menglian Ma, Ping Guo +2
    BMC NephrologyPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
BibTeX
@article{chen2026association,
  title = {{Association between triglyceride-glucose index and treatment response in primary membranous nephropathy: a retrospective cohort study}},
  author = {Wei Chen and Tan Hou and Weimin Yu},
  journal = {Renal Failure},
  year = {2026},
  month = nov,
  doi = {10.1080/0886022x.2026.2751267},
  url = {https://doi.org/10.1080/0886022x.2026.2751267},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Association between triglyceride-glucose index and treatment response in primary membranous nephropathy: a retrospective cohort study
AU  - Wei Chen
AU  - Tan Hou
AU  - Weimin Yu
PY  - 2026
DA  - 2026/11/04
JO  - Renal Failure
DO  - 10.1080/0886022x.2026.2751267
UR  - https://doi.org/10.1080/0886022x.2026.2751267
AB  - Background/Objectives: The triglyceride-glucose (TyG) index, a marker of insulin resistance, has been linked to chronic kidney disease and proteinuria severity, but its prognostic value for treatment response in primary membranous nephropathy (PMN) is unclear. We evaluated whether baseline TyG predicts 12-month proteinuria remission in PMN.  Methods: We included 363 patients with PMN. The primary outcome was 12-month remission per 2021 KDIGO criteria. Missing covariates were handled by multiple imputation (20 datasets). Multivariable logistic regression adjusted for anti-PLA2R antibody (continuous, per 100 RU/mL), albumin, 24-hour urine protein, age, sex, comorbidities, and treatment group. Sensitivity analyses included TyG tertiles, restriction to standard immunotherapy, complete remission, binary anti-PLA2R status, eGFR adjustment, log-transformed and restricted cubic spline modeling of anti-PLA2R antibody, complete-case analysis, inverse probability of treatment weighting, post-hoc power analysis, and adjustment for treatment switching.  Results: Among 363 patients, 267 (73.6%) achieved remission. Baseline TyG was not independently associated with remission (OR = 0.839, 95% CI: 0.544–1.293, p = 0.425). Higher anti-PLA2R antibody levels were associated with lower odds of remission when modeled continuously (OR per 100 RU/mL = 0.836, 95% CI: 0.704–0.992, p = 0.041), but not when dichotomized (OR = 0.666, 95% CI: 0.213–2.089, p = 0.484). Addition of TyG minimally improved model discrimination (AUC 0.714 to 0.716). Results were consistent across sensitivity analyses.  Conclusions: Baseline TyG was not independently associated with 12-month remission in PMN and provided minimal incremental predictive value. However, a moderate association cannot be excluded given the confidence interval. Anti-PLA2R antibody level showed an inverse association when modeled continuously.
SN  - 0886-022X
SN  - 1525-6049
ER  -